IBDEI32I ; ; 19-NOV-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,51430,1,4,0)
 ;;=4^M22.41
 ;;^UTILITY(U,$J,358.3,51430,2)
 ;;=^5011186
 ;;^UTILITY(U,$J,358.3,51431,0)
 ;;=M22.42^^222^2480^1
 ;;^UTILITY(U,$J,358.3,51431,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,51431,1,3,0)
 ;;=3^Chondromalacia patellae, lft knee
 ;;^UTILITY(U,$J,358.3,51431,1,4,0)
 ;;=4^M22.42
 ;;^UTILITY(U,$J,358.3,51431,2)
 ;;=^5011187
 ;;^UTILITY(U,$J,358.3,51432,0)
 ;;=M23.91^^222^2480^4
 ;;^UTILITY(U,$J,358.3,51432,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,51432,1,3,0)
 ;;=3^Intrnl derangement of rt knee, unspec
 ;;^UTILITY(U,$J,358.3,51432,1,4,0)
 ;;=4^M23.91
 ;;^UTILITY(U,$J,358.3,51432,2)
 ;;=^5133806
 ;;^UTILITY(U,$J,358.3,51433,0)
 ;;=M23.92^^222^2480^3
 ;;^UTILITY(U,$J,358.3,51433,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,51433,1,3,0)
 ;;=3^Intrnl derangement of lft knee, unspec
 ;;^UTILITY(U,$J,358.3,51433,1,4,0)
 ;;=4^M23.92
 ;;^UTILITY(U,$J,358.3,51433,2)
 ;;=^5133807
 ;;^UTILITY(U,$J,358.3,51434,0)
 ;;=M02.00^^222^2481^1
 ;;^UTILITY(U,$J,358.3,51434,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,51434,1,3,0)
 ;;=3^Arthropathy following intest bypass, unspec site
 ;;^UTILITY(U,$J,358.3,51434,1,4,0)
 ;;=4^M02.00
 ;;^UTILITY(U,$J,358.3,51434,2)
 ;;=^5009718
 ;;^UTILITY(U,$J,358.3,51435,0)
 ;;=L52.^^222^2481^2
 ;;^UTILITY(U,$J,358.3,51435,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,51435,1,3,0)
 ;;=3^Erythema nodosum
 ;;^UTILITY(U,$J,358.3,51435,1,4,0)
 ;;=4^L52.
 ;;^UTILITY(U,$J,358.3,51435,2)
 ;;=^42065
 ;;^UTILITY(U,$J,358.3,51436,0)
 ;;=L40.59^^222^2481^3
 ;;^UTILITY(U,$J,358.3,51436,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,51436,1,3,0)
 ;;=3^Psoriatic arthropathy, oth
 ;;^UTILITY(U,$J,358.3,51436,1,4,0)
 ;;=4^L40.59
 ;;^UTILITY(U,$J,358.3,51436,2)
 ;;=^5009170
 ;;^UTILITY(U,$J,358.3,51437,0)
 ;;=M02.30^^222^2481^4
 ;;^UTILITY(U,$J,358.3,51437,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,51437,1,3,0)
 ;;=3^Reiter's disease, unspec site
 ;;^UTILITY(U,$J,358.3,51437,1,4,0)
 ;;=4^M02.30
 ;;^UTILITY(U,$J,358.3,51437,2)
 ;;=^5009790
 ;;^UTILITY(U,$J,358.3,51438,0)
 ;;=M94.1^^222^2481^5
 ;;^UTILITY(U,$J,358.3,51438,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,51438,1,3,0)
 ;;=3^Relapsing polychondritis
 ;;^UTILITY(U,$J,358.3,51438,1,4,0)
 ;;=4^M94.1
 ;;^UTILITY(U,$J,358.3,51438,2)
 ;;=^5015328
 ;;^UTILITY(U,$J,358.3,51439,0)
 ;;=90471^^223^2482^1^^^^1
 ;;^UTILITY(U,$J,358.3,51439,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,51439,1,2,0)
 ;;=2^90471
 ;;^UTILITY(U,$J,358.3,51439,1,3,0)
 ;;=3^Immunization Admin (use w/ Vaccs)
 ;;^UTILITY(U,$J,358.3,51440,0)
 ;;=90472^^223^2482^2^^^^1
 ;;^UTILITY(U,$J,358.3,51440,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,51440,1,2,0)
 ;;=2^90472
 ;;^UTILITY(U,$J,358.3,51440,1,3,0)
 ;;=3^Immunization Admin, ea add
 ;;^UTILITY(U,$J,358.3,51441,0)
 ;;=90632^^223^2482^6^^^^1
 ;;^UTILITY(U,$J,358.3,51441,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,51441,1,2,0)
 ;;=2^90632
 ;;^UTILITY(U,$J,358.3,51441,1,3,0)
 ;;=3^Hepatitis A Vaccine
 ;;^UTILITY(U,$J,358.3,51442,0)
 ;;=90746^^223^2482^7^^^^1
 ;;^UTILITY(U,$J,358.3,51442,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,51442,1,2,0)
 ;;=2^90746
 ;;^UTILITY(U,$J,358.3,51442,1,3,0)
 ;;=3^Hepatitis B Vaccine (3 Doses)
 ;;^UTILITY(U,$J,358.3,51443,0)
 ;;=90636^^223^2482^8^^^^1
 ;;^UTILITY(U,$J,358.3,51443,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,51443,1,2,0)
 ;;=2^90636
 ;;^UTILITY(U,$J,358.3,51443,1,3,0)
 ;;=3^Hepatitis A&B Vaccine
 ;;^UTILITY(U,$J,358.3,51444,0)
 ;;=90707^^223^2482^9^^^^1
 ;;^UTILITY(U,$J,358.3,51444,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,51444,1,2,0)
 ;;=2^90707
